AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma - LARVOL DELTA

Trop2-directed antibody-drug conjugate shr-a1921 combined with pd-l1 inhibitor adebrelimab for patients with advanced triple negative breast cancer: results from a phase 2, multi-cohort, open-label, non-controlled trial (SABCS 2025) - "Abstract is embargoed at this time."

Clinical • Metastases • P2 data • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Phase II Clinical Study of Trastuzumab Rezetecan (SHR-A1811) or in Combination With Adebrelimab (SHR-1316) for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (ChiCTR) - P2 | N=96 | Recruiting | Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

New P2 trial • Oncology • Solid Tumor • Urothelial Cancer • HER-2 • PD-L1

A single-arm, multicenter clinical study of neoadjuvant therapy of Adebrelimab combined with SOX for locally advanced resectable gastric or gastroesophageal adenocarcinoma (ChiCTR) - P1 | N=35 | Not yet recruiting | Sponsor: Lianyungang First People's Hospital; Lianyungang First People's Hospital

New P1 trial • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A Multicenter, Open-Label Phase II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of SHR2554 Tablets in Combination with Other Antitumor Therapies in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma (ChiCTR) - P2 | N=366 | Recruiting | Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital

New P2 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18 • HER-2 • PD-L1

Adebrelimab combined with etoposide plus platinum followed by adebrelimab and etoposide soft capsules for maintenance treatment of extensive-stage small cell lung cancer: a single-arm phase II trial (ChiCTR) - P4 | N=40 | Recruiting | Sponsor: Jiangsu Cancer Hospital; Jiangsu Cancer Hospital

New P4 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Adebrelimab combined with vunakizumab for first-line maintenance treatment of extensive-stage small cell lung cancer: A prospective, single-center, single-arm clinical study (ChiCTR) - P4 | N=43 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University

New P4 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Clinical Study of Adebrelimab Combined with Chemotherapy and Adebrelimab as Neoadjuvant Therapy for NSCLC (ChiCTR) - P=N/A | N=36 | Not yet recruiting | Sponsor: Peking University People's Hospital; Peking University People's Hospital

New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A clinical research on adbrelimab combined with chemotherapy for perioperative adjuvant therapy of locally advanced esophageal squamous cell carcinoma (ChiCTR) - P4 | N=70 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University

New P4 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Clinical study of adebrelimab in the treatment of NSCLC treated with ICIs therapy (ChiCTR) - P4 | N=30 | Not yet recruiting | Sponsor: Anqing Municipal Hospital; Anqing Municipal Hospital

New P4 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Adebrelimab Combined with Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for ES-SCLC: A Single-Arm, Single-Center, Exploratory Clinical Study (ChiCTR) - P2 | N=32 | Not yet recruiting | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Radiotherapy combined with NALIRI (irinotecan liposome injection II in conjunction with 5-FU/LV) and Adebrelimab as first-line treatment for unresectable locally advanced or oligometastatic malignant biliary tract tumors: A prospective, single-arm, single-center, exploratory study (ChiCTR) - P4 | N=37 | Not yet recruiting | Sponsor: Fudan University Affiliated Zhongshan Hospital; Fudan University Affiliated Zhongshan Hospital

New P4 trial • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma

A single-center, single-arm phase II clinical study of albumin-bound paclitaxel combined with carboplatin and adebrelimab for neoadjuvant treatment of thymic carcinoma (ChiCTR) - P4 | N=40 | Not yet recruiting | Sponsor: Nanjing Drum Tower hospital; Nanjing Drum Tower hospital

New P4 trial • Oncology • Solid Tumor • Thymic Carcinoma • Thymus Cancer

A Single-Arm, Single-Center Phase II Clinical Study on Sequential Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Following First-Line Treatment with Adibelimab in Combination with Chemotherapy (ChiCTR) - P2 | N=35 | Recruiting | Sponsor: Hunan Cancer Hospital; Hunan Cancer Hospital

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Phase II Study of Induction with Immunotherapy, Targeted Therapy, and Chemotherapy, Followed by Maintenance with Immunotherapy, Targeted Therapy, and a PARP Inhibitor in Platinum-Resistant Ovarian Cancer (ChiCTR) - P=N/A | N=32 | Not yet recruiting | Sponsor: First Hospital Of Nanping; First Hospital Of Nanping

New trial • Platinum resistant • Oncology • Ovarian Cancer • Solid Tumor

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P3 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Adebrelimab combined with TCb-AC (albumin paclitaxel+carboplatin doxorubicin+cyclophosphamide) neoadjuvant therapy for early or locally advanced triple negative breast cancer:a single arm study (ChiCTR) - P=N/A | N=20 | Completed | Sponsor: Yuncheng Central Hospital; Yuncheng Central Hospital

IO biomarker • New trial • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PD-L1 • PGR

A Phase II Single-Arm Prospective Clinical Study of Adebrelimab Combined with Chemotherapy With or Without Bevacizumab as First-Line Treatment for Recurrent/Persistent/Metastatic Cervical Cancer (ChiCTR) - P2 | N=50 | Not yet recruiting | Sponsor: First Hospital Of Nanping; First Hospital Of Nanping

New P2 trial • Cervical Cancer • Oncology • Solid Tumor • PD-L1

A single-arm, exploratory clinical study of adebelimab combined with chemotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma (ChiCTR) - P4 | N=58 | Recruiting | Sponsor: Shandong Provincial Hospital; Shandong Provincial Hospital

New P4 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Hepatic arterial infusion or intravenous infusion of Adebrelimab, combined with Bevacizumab and hepatic arterial infusion chemotherapy as first-line treatment of advanced unresectable hepatocellular carcinoma: a multicenter, open label, randomized phase II clinical trial (ESMO-IO 2025) - No abstract available

Clinical • Metastases • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

SHR-A1811 combined with adebrelimab in HR-/HR-low, HER2-low metastatic breast cancer: Preliminary results from an open-label, single-arm, phase II trial (ESMO 2025) - P2 | "The HER2-directed Antibody-Drug Conjugate (ADC) drug T-DXd has shown significant benefits in the entire HER-2 low MBC population, including those with HR- or low HR expression. 10 pts (41.67%) experienced grade ≥3 TEAEs. Conclusions Preliminary results of SHR-A1811 combined with Adebrelimab in HR-negative/HR-low, HER2-low MBC pts yields promising antitumor efficacy with manageable toxicity."

Clinical • IO biomarker • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • ER • HER-2

Efficacy of adebrelimab with chidamide, gemcitabine, and S-1 in locally advanced or metastatic pancreatic cancer: A phase II study (ESMO-IO 2025) - No abstract available

Clinical • Metastases • P2 data • Oncology • Pancreatic Cancer • Solid Tumor

Neoadjuvant adebrelimab plus chemotherapy for locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: A single-arm, open-label, phase II trial (ESMO 2025) - P2 | "Based on the PRODIGY trial, docetaxel, oxaliplatin, and S-1 (DOS) is a neoadjuvant standard...ctDNA clearance may serve as a highly specific predictor of pathological response. Survival and biomarker (MRD) analyses ongoing."

Clinical • IO biomarker • Metastases • P2 data • Tumor mutational burden • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Microsatellite Instability • Oncology • Solid Tumor • MSI • TMB

Interim Analysis of Adebrelimab plus Famitinib as Later-line Treatment for Extensive-Stage Small Cell Lung Cancer: A Phase 2 Clinical Trial (ESMO Asia 2025) - No abstract available

Clinical • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

First-line adebrelimab plus anti-angiogenic therapy in PD-L1 ≥50% NSCLC with brain metastases: Updated results from the BRAIN-AF01 study (ESMO 2025) - P2 | "This study reports updated outcomes of Adebrelimab with either famitinib or bevacizumab in patients with PD-L1 ≥50% NSCLC and brain metastases. Conclusions Adebrelimab plus anti-angiogenic therapy demonstrated promising efficacy and durable intracranial control with manageable toxicity in PD-L1 high NSCLC with brain metastases. Pharmacokinetic and MRI findings support CNS activity, warranting further investigation."

Clinical • IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1